企業プロフィール
Neurogene 株価・ニュース・カタリスト
- ティッカー:
- NGNE
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
36.68 USD (+1.49%)
終値
最終更新: 2026年8月17日
413M USD
時価総額
株価変動の要因
As of Aug 17, 2026, NGNE closed up 1.49% at $36.68. No new same-company headline was identified in the current news window.
企業概要
事業概要
Neurogene is a gene-therapy company focused on rare neurological diseases. Its story is centered on bringing genetic medicine to severe CNS disorders with very high unmet need.
所在地とセクター分類
Neurogene is headquartered in the United States and listed on NASDAQ. It sits in gene therapy and neuroscience biotechnology.
ビジネスモデルの特徴
The company depends on clinical progress, manufacturing execution, and the ability to fund a narrow rare-disease pipeline. Investors watch early data and safety closely.
バイオ業界での位置付け
Neurogene occupies a premium but high-risk gene-therapy niche within biotech. The stock is catalyst-sensitive because the company’s value is tightly linked to a small set of gene-therapy assets.
今後のカタリスト
- Neurogene’s catalysts are NGN-401 and the Rett-syndrome / neurogenetic platform, with each update potentially moving the stock quickly. The company remains early and highly data-dependent.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。